---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-015569"
form_type: "8-K"
ticker: "ANNX"
cik: "0001528115"
company_name: "Annexon, Inc."
filed_at: "2022-08-08T23:59:59+00:00"
generated_at: "2026-06-24T02:46:08.236312+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Annexon Q2 net loss $37.1M; cash $177.6M, extended runway into H2 2025 via $130M private placement

## Summary
- Net loss of $37.1M ($0.96/share) vs. $31.3M ($0.82/share) in Q2 2021.
- Cash and short-term investments $177.6M at June 30, 2022, plus $130M from July private placement.
- Operating runway extended into second half of 2025.
- FDA granted Fast Track designation to ANX007 for geographic atrophy; Phase 2 enrolled.
- Phase 1 trials initiated for oral small molecule ANX1502 and next-gen mAb ANX105.

## SEC filing metadata
- accession: 0000950170-22-015569
- form_type: 8-K
- ticker: ANNX
- cik: 0001528115
- company_name: Annexon, Inc.
- filed_at: 2022-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1528115/000095017022015569/0000950170-22-015569-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1528115/000095017022015569/annx-20220808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-015569
- JSON: https://secwatch.observer/filing/0000950170-22-015569.json
- Plain text: https://secwatch.observer/filing/0000950170-22-015569.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.